Novo Nordisk Aktie

31,87 EUR -0,11 EUR -0,34 %

18:38:14

FSE

31,00 EUR -1,06 EUR -3,29 %

17:50:05

GVIE

Novo Nordisk jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.141,78 Mrd. EUR

KGV14,11Div. Rendite3,60%

WKNA3EU6F

ISINDK0062498333

SymbolNONOF

Novo Nordisk Aktien News

Sortieren:Datum Meistgelesen

12.06.25GlobeNewswireNovo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

10.06.25GlobeNewswireADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care

16.05.25GlobeNewswireNovo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

WerbungNovo Nordisk-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

16.05.25GlobeNewswireNovo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

14.05.25GlobeNewswireNovo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

12.05.25GlobeNewswireNovo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presente

09.05.25GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

07.05.25GlobeNewswireNovo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025

03.04.25GlobeNewswireNovo Nordisk announces changes in Executive Management

29.03.25GlobeNewswireNovo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

29.03.25GlobeNewswireOzempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

27.03.25GlobeNewswireResolutions from the Annual General Meeting of Novo Nordisk A/S

24.03.25GlobeNewswireThe United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

10.03.25GlobeNewswireNovo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

27.02.25GlobeNewswireNovo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

07.02.25GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

07.02.25GlobeNewswireNovo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

05.02.25GlobeNewswireNovo Nordisk files annual report with the SEC

05.02.25GlobeNewswireNovo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

04.02.25GlobeNewswireNovo Nordisk A/S - share repurchase programme

27.01.25GlobeNewswireNovo Nordisk A/S - share repurchase programme

24.01.25GlobeNewswireNovo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

20.01.25GlobeNewswireNovo Nordisk A/S - share repurchase programme

17.01.25GlobeNewswireNovo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

13.01.25GlobeNewswireNovo Nordisk A/S - share repurchase programme

08.01.25GlobeNewswireValo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

20.12.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

20.12.24GlobeNewswireNovo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

18.12.24GlobeNewswireThe acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed

16.12.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

16.12.24GlobeNewswireNovo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark

14.12.24GlobeNewswireNovo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

12.12.24GlobeNewswireNovo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events

09.12.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

06.12.24GlobeNewswireThe European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

02.12.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

25.11.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

19.11.24GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

18.11.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

13.11.24GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk News

Novo Nordisk News: auf dieser Seite finden Sie alle Novo Nordisk News und Nachrichten zur Novo Nordisk Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.